Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5845581 | Pulmonary Pharmacology & Therapeutics | 2016 | 31 Pages |
Abstract
Inhaled glucocorticoids are the mainstay of asthma treatment. Indeed, such therapeutic agents effectively interfere with many pathogenic circuits underpinning asthma. Among these drugs, during the last decades budesonide has been probably the most used molecule in both experimental studies and clinical practice. Therefore, a large body of evidence clearly shows that budesonide, either alone or in combination with long-acting bronchodilators, provides a successful control of asthma in many patients ranging throughout the overall spectrum of disease severity. These excellent therapeutic properties of budesonide basically depend on its molecular mechanisms of action, capable of inhibiting within the airways the activity of multiple immune-inflammatory and structural cells involved in asthma pathobiology.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Francesco Fabiano, Rosa Terracciano, Maria Gabriella Matera, Rosario Maselli,